English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
 Local TagsRelease HistoryDetailsSummary
  Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival

Kristiansen, G., Pilarsky, C., Wissmann, C., Kaiser, S., Bruemmendorf, T., Roepcke, S., et al. (2005). Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. The Journal of Pathology, 205(3), 359-376. doi:10.1002/path.1676.

Item is

 

show all hide all

Basic

show hide
Item Permalink: https://hdl.handle.net/11858/00-001M-0000-0010-86F6-6 Version Permalink: https://hdl.handle.net/11858/00-001M-0000-0010-86F7-4
Genre: Journal Article
Alternative Title : J Path

Files

show Files
hide Files
:
fulltext_ID=109752103&PLACEBO=IE.pdf (Any fulltext), 807KB
 
File Permalink:
-
Name:
fulltext_ID=109752103&PLACEBO=IE.pdf
Description:
-
OA-Status:
Visibility:
Restricted (Max Planck Institute for Molecular Genetics, MBMG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
eDoc_access: MPG
License:
-

Locators

show

Creators

show
hide
 Creators:
Kristiansen, Glen, Author
Pilarsky, Christian, Author
Wissmann, Christoph, Author
Kaiser, Simone, Author
Bruemmendorf, Thomas, Author
Roepcke, Stefan1, Author
Dahl, Edgar, Author
Hinzmann, Bernd, Author
Specht, Thomas, Author
Pervan, Janja, Author
Stephan, Carsten, Author
Loening, Stefan, Author
Dietel, Manfred, Author
Rosenthal, André, Author
Affiliations:
1Max Planck Society, ou_persistent13              

Content

show
hide
Free keywords: prostate cancer tumour profiling microarray hybridization immunohistochemistry CD166 CD24
 Abstract: In order to screen for differentially expressed genes that might be useful in diagnosis or therapy of prostate cancer we have used a custom made Affymetrix GeneChip containing 3950 cDNA fragments. Expression profiles were obtained from 42 matched pairs of mRNAs isolated from microdissected malignant and benign prostate tissues. Applying three different bioinformatic approaches to define differential gene expression, we found 277 differentially expressed genes, of which 98 were identified by all three methods. Fourteen per cent of these genes were not found in other expression studies, which were based on bulk tissue. Resultant candidate genes were further validated by quantitative RT-PCR, mRNA in situ hybridization and immunohistochemistry. AGR2 was over-expressed in 89% of prostate carcinomas, but did not have prognostic significance. Immunohistologically detected over-expression of MEMD and CD24 was identified in 86% and 38.5% of prostate carcinomas respectively, and both were predictive of PSA relapse. Combined marker analysis using MEMD and CD24 expression proved to be an independent prognostic factor (RR = 4.7, p = 0.006) in a Cox regression model, and was also superior to conventional markers. This combination of molecular markers thus appears to allow improved prediction of patient prognosis, but should be validated in larger studies. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Details

show
hide
Language(s): eng - English
 Dates: 2005-02-01
 Publication Status: Issued
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: eDoc: 265199
DOI: 10.1002/path.1676
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: The Journal of Pathology
  Alternative Title : J Path
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 205 (3) Sequence Number: - Start / End Page: 359 - 376 Identifier: ISSN: 0022-3417